| Abstrakt: |
A recent report from the Regional Institute of Oncology in Iasi, Romania, highlights the effectiveness of Olaparib, a novel therapy, in treating advanced ovarian cancer with BRCA1 mutations. The report presents two cases of long-term survival in patients who responded well to Olaparib maintenance therapy after initial chemotherapy. The first case involves a 42-year-old patient with a rare BRCA1 mutation and a family history of ovarian and breast cancers, while the second case involves a 55-year-old postmenopausal woman. These cases demonstrate the potential benefits of Olaparib and PARP inhibitors in personalized oncology treatment for ovarian cancer. [Extracted from the article] |
